Physician profile
Eddison Ramsaran
NPI 1225015811
$4,824.81
in general payments reported to CMS, 2019-2025
20 companies · $839 in 2025
The $839 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,729 · 2020: $185 · 2021: $190 · 2022: $315 · 2023: $675 · 2024: $891 · 2025: $839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,405.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,230.45 | 2019-2022 | |
| Pfizer INC. | $833.16 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $470.13 | 2019-2025 | Lifevest |
| Amgen INC. | $452.94 | 2019-2025 | Repatha, Repatha |
| Abiomed | $423.18 | 2024-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $402.44 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $225.60 | 2021-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $145.98 | 2019-2025 | Camzyos, Eliquis |
| Bardy Diagnostics, INC. | $125.00 | 2020 | |
| Penumbra, INC. | $96.01 | 2025 | Indigo System |
| Medtronic, INC. | $90.67 | 2021-2023 | Azure Xt Dr Mri Surescan, Abre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.37 | 2019-2025 | Jardiance |
| Scpharmaceuticals INC. | $37.55 | 2024 | |
| Janssen Pharmaceuticals, INC | $35.17 | 2022 | |
| Amarin Pharma, INC. | $34.78 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $34.13 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $28.80 | 2025 | Attruby |
| Incyte Corporation | $24.98 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.98 | 2021 | |
| Alnylam Pharmaceuticals INC. | $22.49 | 2025 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eddison Ramsaran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.